CBD for Individuals at Risk for Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2029-04-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized controlled trial designed to test the effects of
cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, behavioral
and clinical measures, with putative mechanisms of CBD action.